Susquehanna International Group, LLP Tarsus Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$21.54 - $34.6 $73,236 - $117,640	-3,400 Reduced 10.97%	27,600 $907,000
Q2 2024 Aug 15, 2024	BUY	$25.17 - $38.73 $143,469 - $220,760	5,700 Added 22.53%	31,000 $842,000
Q1 2024 May 07, 2024	BUY	$19.61 - $39.22 $496,133 - $992,266	25,300 New	25,300 $919,000
Q3 2023 Nov 14, 2023	BUY	$14.75 - $24.62 $53,100 - $88,632	3,600 Added 23.23%	19,100 $339,000
Q2 2023 Aug 11, 2023	BUY	$11.57 - $19.63 $179,335 - $304,265	15,500 New	15,500 $280,000
Q3 2022 Nov 14, 2022	SELL	$14.08 - $18.5 $15,488 - $20,350	-1,100 Reduced 4.01%	26,300 $450,000
Q2 2022 Aug 15, 2022	BUY	$11.08 - $19.08 $303,592 - $522,791	27,400 New	27,400 $400,000

170

43.3M

484K

4.1K

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $1.41B
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.